Get started
Live feed
PRReleasevia Quantisnow
Fate Therapeutics Inc. logo

Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting

ByQuantisnow··Wall Street's wire, on your screen.
Stocks in this Quantisnow insight

Historical context for FATE

Across the 21 sessions after earlier FATE headlines, the stock closed higher 10 times and lower 10 times, with a median move of 5.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.

FATE close-to-close change in the session after earlier headlines
SessionEarlier headlineFATESPY
May 21, 2026Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases+14.1%+0.2%
May 19, 2026Jefferies resumed coverage on Fate Therapeutics+9.2%-0.7%
May 13, 2026Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates-5.1%+0.6%
May 11, 2026Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting-8.8%+0.2%
May 5, 2026Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819+31.1%+0.8%
May 4, 2026Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseasesand 1 other headline that session+17.6%-0.4%
Quantisnow market dataNASDAQ
Fate Therapeutics Inc. logo
FATE
Fate Therapeutics Inc.
Market cap
30-day
Sector
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Listed since
2013
Get push alerts for FATE

Follow FATE and get a push notification the moment its next story breaks.

Full FATE profile on Quantisnow

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track FATE (Fate Therapeutics Inc.) and more on Quantisnow.